NATAN DAVID 4
4 · TITAN PHARMACEUTICALS INC · Filed Jul 28, 2023
Insider Transaction Report
Form 4
NATAN DAVID
Director
Transactions
- Award
Common Stock
2023-07-26+50,000→ 50,000 total - Award
Option to Purchase Common Stock
2023-06-29+25,000→ 25,000 totalExercise: $1.52Exp: 2022-08-15→ Common Stock (25,000 underlying) - Award
Option to Purchase Common Stock
2023-06-29+100,000→ 100,000 totalExercise: $1.31Exp: 2022-09-15→ Common Stock (100,000 underlying)
Footnotes (3)
- [F1]The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.
- [F2]The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.
- [F3]The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022.